EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC 4.0

A Delicate Balance: Immunotherapy for Endometrial Cancer in a Patient With Multiple Sclerosis

Antonio Ruggiero iD, Chiara Redemagni, Cristina Angela Camnasio, Vittoria Morteo, Federica Carcagni, Simone Zatti, Ilaria Strada, Marianna Roccio, Eleonora Rigoni, Chiara Cassani, Elena Colombo

Journal of Medical Cases · 2026-08 · 17 (8) · 371-375

DOI: 10.14740/jmc5260 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Medical Cases, 2026-08. Verfasst von Antonio Ruggiero und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple sclerosis (MS) is a chronic immune-mediated disease that may complicate oncological management, particularly when immune checkpoint inhibitors (ICIs) are indicated. Evidence regarding the safety of ICIs in patients with pre-existing MS remains limited, especially in older patients and in the first-line treatment of endometrial cancer (EC). We present the case of a 71-year-old woman with relapsing–remitting MS (radiologically stable for > 12 months) and stage IIIC1 mismatch repair–deficient/microsatellite instability–high EC who was treated with first-line carboplatin–paclitaxel combined with programmed cell death protein 1 (PD-1) inhibitor dostarlimab. Ozanimod, which had been used to manage her MS, was temporarily discontinued prior to chemotherapy. No clinical relapses or new magnetic resonance imaging (MRI) activity were observed during combination therapy or throughout a 12-month interim follow-up. Dostarlimab maintenance therapy is ongoing. This case suggests that ICIs may be cautiously integrated into the treatment of selected patients with MS and advanced EC when baseline neurological stability, patient age, and prior disease-modifying therapy are carefully considered. Close interdisciplinary collaboration and structured neurological monitoring are essential. Longer follow-up is required to confirm long-term neurological safety.

Schlagwörter

Stichwörter der Autor:innen

Disease modifying therapiesDostarlimabEndometrial cancerImmune checkpoint inhibitorsMultiple sclerosis

Autor:innen und Institutionen

  • Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
  • Unit of Obstetrics and Gynecology, IRCCS S. Matteo Foundation, Pavia, Italy.
  • These authors contributed equally to this article.
  • Multiple Sclerosis Centre, IRCCS Mondino Foundation, Pavia, Italy.
  • These authors share the co-last authorship.

ORCID-Profile: Antonio Ruggiero

Zitieren

APA

Ruggiero, A., Redemagni, C., Camnasio, C. A., Morteo, V., Carcagni, F., Zatti, S., Strada, I., Roccio, M., Rigoni, E., Cassani, C., & Colombo, E. (2026). A Delicate Balance: Immunotherapy for Endometrial Cancer in a Patient With Multiple Sclerosis. Journal of Medical Cases, 17(8), 371-375. https://doi.org/10.14740/jmc5260

Vancouver

Ruggiero A, Redemagni C, Camnasio CA, Morteo V, Carcagni F, Zatti S, et al. A Delicate Balance: Immunotherapy for Endometrial Cancer in a Patient With Multiple Sclerosis. Journal of Medical Cases. 2026;17(8):371-375. doi:10.14740/jmc5260

BibTeX
@article{Ruggiero2026,
  author = {Ruggiero, Antonio and Redemagni, Chiara and Camnasio, Cristina Angela and Morteo, Vittoria and Carcagni, Federica and Zatti, Simone and Strada, Ilaria and Roccio, Marianna and Rigoni, Eleonora and Cassani, Chiara and Colombo, Elena},
  title = {A Delicate Balance: Immunotherapy for Endometrial Cancer in a Patient With Multiple Sclerosis},
  journal = {Journal of Medical Cases},
  year = {2026},
  volume = {17},
  number = {8},
  pages = {371--375},
  doi = {10.14740/jmc5260}
}
Kostenlos starten →